Core One Labs, Inc. is a biotechnology company, which engages in the manufacture of cannabis-infused strips. The company is headquartered in Vancouver, British Columbia. The firm is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. The company is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. The company also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.
最新の財務諸表(Form-10K)によると、Core One Labs Inc.の総資産は$8で、純損失は$-19です。
CLABFの主要な財務比率は何ですか?
Core One Labs Inc.の流動比率は8、純利益率は0、1株当たり売上高は$0です。
Core One Labs Inc.の収益はセグメントまたは地域別にどのように分けられていますか?
Core One Labs Inc. の最大収益セグメントは Olefins and Derivatives で、最新の利益発表における収益は 13,732,000,000 です。地域別に見ると、Malaysia が Core One Labs Inc. の主要市場であり、収益は 7,536,000,000 です。